Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection

Optimizing the treatment of chronic hepatitis due to hepatitis C virus genotypes 2 and 3: a review

(2009) Giuseppe Tarantino et al.   LIVER INTERNATIONAL

Randomized comparison of 12 or 24 weeks of peginterferon α-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

(2008) Martin Lagging et al.   HEPATOLOGY

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3

(2008) Peter Ferenci et al.   HEPATOLOGY

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

(2008) Véronique Loustaud-Ratti et al.   HEPATOLOGY

The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon

(2008) D. Aguilar Marucco et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ribavirin: Current role in the optimal clinical management of chronic hepatitis C

(2008) K. Rajender Reddy et al.   JOURNAL OF HEPATOLOGY

Expert opinion on the treatment of patients with chronic hepatitis C

(2008) S. Zeuzem et al.   JOURNAL OF VIRAL HEPATITIS